<unk>  (trade name Repatha) is a monoclonal antibody medication designed for the treatment of hyperlipidemia.<unk>  is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that targets LDL receptors for degradation and its inhibition thereby enhances the liver's ability to remove LDL-C, or "bad" cholesterol, from the blood.
Evolocumab
Olaratumab
Emapalumab
Ustekinumab
Alirocumab
Tralokinumab
Anifrolumab
Dupilumab